Genetic Analysis AS: Mandatory notification of trade – Primary Insiders

OSLO, NORWAY – 26 May 2023: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.

Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS yesterday bought 33.250 GEAN shares at an average price of 1,71 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 225.290 shares and 26.909 tradable subscription rights GEAN T02.

For more information, please contact:
Eilert Aamodt, Chief Financial Officer
E-mail: ea@genetic-analysis.com

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com